Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20391134 | 0.85 | ALDH1A1 (0.39) | EGLN1GRIA1ALDH1A1GAAMEN1 | |
| SCHEMBL889374 | 0.82 | GRIA1 (0.43) | EGLN1GRIA1ACACBNOTUMOGA | |
| SCHEMBL890209 | 0.82 | MAPT (0.47) | EGLN1GRIA1ACACBNOTUMALDH1A1 | |
| SCHEMBL18948574 | 0.78 | EGLN1 (0.36) | EGLN1GRIA1ACACBNOTUM | |
| SCHEMBL13623091 | 0.78 | NOS3 (0.48) | ALDH1A1MEN1NPC1MAPTRAB9A | |
| SCHEMBL20390799 | 0.78 | GRIN2D (0.38) | OGA | |
| SCHEMBL13615808 | 0.77 | CPB2 (0.36) | EGLN1GRIA1ALDH1A1HCAR2 | |
| SCHEMBL20392745 | 0.77 | IDH1 (0.40) | EGLN1GRIA1NPC1MAPTRAB9A | |
| SCHEMBL13659737 | 0.76 | NOTUM (0.51) | NOTUMALDH1A1GAAALOX12HTT | |
| SCHEMBL18782798 | 0.76 | GRIA1 (0.39) | EGLN1GRIA1ACACBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009075923-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | EGLN1 2246/4885GRIA1 4502/4885ACACB 525/4885 |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | EGLN1 2246/4885GRIA1 4502/4885ACACB 525/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | EGLN1 2163/4885GRIA1 4477/4885ACACB 602/4885 |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | EGLN1 388/4885GRIA1 4825/4885ACACB 1575/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | EGLN1 2246/4885GRIA1 4502/4885ACACB 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.